Table 4 Physician preference weights for (a) France; (b) Germany; (c) UK
From: Physicians’ preferences for bone metastases treatments in France, Germany and the United Kingdom
Attribute Name | Level | Preference weight (95% CI) | p value |
|---|---|---|---|
(a) France | |||
Time until first SRE | 28 months | 1.44 (1.15, 1.72) | 0.000 |
18 months | − 0.13 (− 0.26, 0.01) | 0.068 | |
10 months | −1.31 (− 1.60, − 1.02) | 0.000 | |
Time until a 2-point increase in pain on the BPI | 10 months | 0.36 (0.18, 0.54) | 0.000 |
6 months | 0.18 (0.03, 0.33) | 0.019 | |
3 months | −0.54 (− 0.72, − 0.36) | 0.000 | |
Risk of ONJ each year | None | 0.15 (−0.02, 0.31) | 0.086 |
1 out of 100 (1%) | 0.22 (0.07, 0.37) | 0.005 | |
5 out of 100 (5%) | −0.37 (−0.54, − 0.19) | 0.000 | |
Risk of 0.5 mg/dL increase in baseline creatinine each year | None | 0.93 (0.68, 1.17) | 0.000 |
4 out of 100 (4%) | −0.07 (−0.23, 0.10) | 0.427 | |
10 out of 100 (10%) | −0.86 (−1.09, − 0.64) | 0.000 | |
Mode of administration | Daily oral tablet | 0.57 (0.35, 0.79) | 0.000 |
Injection every 4 weeks | 0.12 (−0.08, 0.31) | 0.239 | |
15-min infusion every 4 weeks | −0.04 (− 0.24, 0.16) | 0.677 | |
120-min infusion every 4 weeks | −0.64 (− 0.88, 0.40) | 0.000 | |
(b) Germany | |||
Time until first SRE | 28 months | 1.48 (1.19, 1.78) | 0.000 |
18 months | −0.31 (−0.47, − 0.16) | 0.000 | |
10 months | −1.17 (−1.46, −0.88) | 0.000 | |
Time until a 2-point increase in pain on the BPI | 10 months | 0.98 (0.70, 1.25) | 0.000 |
6 months | 0.04 (−0.12, 0.19) | 0.649 | |
3 months | −1.01 (−1.19, −0.83) | 0.000 | |
Risk of ONJ each year | None | 0.40 (0.22, 0.58) | 0.000 |
1 out of 100 (1%) | 0.27 (0.11, 0.44) | 0.001 | |
5 out of 100 (5%) | −0.67 (−0.85, −0.50) | 0.000 | |
Risk of 0.5 mg/dL increase in baseline creatinine each year | None | 0.80 (0.58, 1.01) | 0.000 |
4 out of 100 (4%) | 0.11 (−0.08, 0.29) | 0.264 | |
10 out of 100 (10%) | −0.90 (−1.13, − 0.68) | 0.000 | |
Mode of administration | Daily oral tablet | 0.30 (0.08, 0.52) | 0.008 |
Injection every 4 weeks | 0.41 (0.20, 0.63) | 0.000 | |
15-min infusion every 4 weeks | 0.21 (0.01, 0.41) | 0.042 | |
120-min infusion every 4 weeks | −0.92 (−1.16, − 0.68) | 0.000 | |
(c) UK | |||
Time until first SRE | 28 months | 1.25 (1.00, 1.51) | 0.000 |
18 months | −0.08 (−0.21, 0.06) | 0.275 | |
10 months | −1.18 (−1.43, −0.92) | 0.000 | |
Time until a 2-point increase in pain on the BPI | 10 months | 0.80 (0.59, 1.01) | 0.000 |
6 months | 0.17 (0.02, 0.32) | 0.028 | |
3 months | −0.97 (−1.18, − 0.76) | 0.000 | |
Risk of ONJ each year | None | 0.28 (0.13, 0.43) | 0.000 |
1 out of 100 (1%) | 0.37 (0.21, 0.53) | 0.000 | |
5 out of 100 (5%) | −0.64 (−0.83, − 0.46) | 0.000 | |
Risk of 0.5 mg/dL increase in baseline creatinine each year | None | 0.89 (0.68, 1.10) | 0.000 |
4 out of 100 (4%) | 0.07 (−0.10, 0.23) | 0.434 | |
10 out of 100 (10%) | −0.96 (−1.17, − 0.74) | 0.000 | |
Mode of administration | Daily oral tablet | 0.69 (0.47, 0.92) | 0.000 |
Injection every 4 weeks | 0.23 (0.05, 0.41) | 0.011 | |
15-min infusion every 4 weeks | −0.13 (− 0.31, 0.06) | 0.175 | |
120-min infusion every 4 weeks | −0.79 (−1.02, − 0.57) | 0.000 | |